Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
Holders of 5% or more of CGEM
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Cullinan Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Biotechnology Value Fund L P | 13G/A | 9.99%5.92M shares | – | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| Lynx1 Capital Management LP | 13G/A | 9.80%5.77M shares | −4.70 ppfrom 14.50% | Aug 14, 20253 filings | Nov 14, 2025 | SEC |
| Kynam Capital Management, LP | 13G | 5.27%3.11M shares | New | Mar 4, 20261 filing | Mar 4, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
12 Schedule 13D and 13G filings on Cullinan Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20265:39 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −5.58 ppfrom 5.58%Below 5% | Mar 13, 2026 | SEC |
| Mar 4, 20263:16 PM ET | Kynam Capital Management, LPand 2 others | 13G | 5.27%3.11M shares | New | Dec 31, 2025 | SEC |
| Feb 17, 20264:10 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%5.92M shares | – | Dec 31, 2025 | SEC |
| Jan 30, 20261:27 PM ET | Vanguard Group Inc | 13G | 5.58%3.30M shares | +0.60 ppfrom 4.98% | Dec 31, 2025 | SEC |
| Nov 14, 20254:03 PM ET | Citadel Advisors LLCand 6 others | 13G/A | 3.40%1.99M shares | −1.70 ppfrom 5.10%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20252:00 PM ET | Lynx1 Capital Management LPand 1 other | 13G/A | 9.80%5.77M shares | −4.70 ppfrom 14.50% | Sep 30, 2025 | SEC |
| Nov 13, 20254:28 PM ET | Flynn James Eand 3 others | 13G/A | 4.95%2.93M shares | –Below 5% | Sep 30, 2025 | SEC |
| Oct 30, 20252:57 PM ET | Vanguard Group Inc | 13G/A | 4.98%2.94M shares | –Below 5% | Sep 30, 2025 | SEC |
| Oct 10, 20256:53 PM ET | Lynx1 Capital Management LPand 1 other | 13G/A | 14.50%8.55M shares | +7.00 ppfrom 7.50% | Oct 8, 2025 | SEC |
| Aug 14, 20256:58 AM ET | Lynx1 Capital Management LPand 1 other | 13G | 7.50%4.40M shares | New | Jun 30, 2025 | SEC |
| Aug 6, 20256:55 PM ET | Citadel Advisors LLCand 6 others | 13G | 5.10%3.01M shares | New | Jul 30, 2025 | SEC |
| Oct 31, 202412:48 PM ET | Franklin Resources Incand 2 others | 13G/A | 3.80%2.19M shares | –Below 5% | Sep 30, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Cullinan Therapeutics, Inc. shares.
No Form 144 notices for Cullinan Therapeutics, Inc. are on file.